康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09926 康方生物

未开盘 04-25 16:09:09

48.450

+1.000

+2.11%

最高49.000	最低46.700	成交量302.31万
今开47.100	昨收47.450	日振幅4.85%
总市值419.51亿	流通市值419.51亿	总股本8.66亿
成交额1.46亿	换手率0.35%	流通股本8.66亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"康方生物","latestPrice":48.45,"timestamp":1714032549019,"preClose":47.45,"halted":0,"volume":3023085,"delay":0,"floatShares":865857176,"shares":865857176,"eps":2.612581,"marketStatus":"未开盘","marketStatusCode":0,"change":1,"latestTime":"04-25 16:09:09","open":47.1,"high":49,"low":46.7,"amount":145728750,"amplitude":0.048472,"askPrice":48.45,"askSize":12000,"bidPrice":48.3,"bidSize":88000,"shortable":3,"etf":0,"ttmEps":2.6111567382914926,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714095000000},"adr":0,"listingDate":1587657600000,"adjPreClose":47.45,"openAndCloseTimeList":[[1714008600000,1714017600000],[1714021200000,1714032000000]],"volumeRatio":0.7266778310181574,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09926/","defaultTab":"news","newsList":[{"id":"2429481398","title":"康方生物04月24日主力资金流入46万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2429481398","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429481398?lang=zh_cn&edition=full","pubTime":"2024-04-24 16:16","pubTimestamp":1713946612,"startTime":"0","endTime":"0","summary":"04月24日, 康方生物股价涨1.06%，报收47.45元，成交金额1.71亿元，换手率0.42%，振幅4.37%，量比0.90。康方生物今日主力资金净流入46万元，连续3日净流入，上一交易日主力净流入173万元，今日环比减少73.41%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为56.25%，平均涨幅为2.52%。该股近5个交易日上涨1.39%，主力资金累计净流出372万元；近20日主力资金累计净流入2729万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042416174587a9d9ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042416174587a9d9ff&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429176635","title":"南向资金4月23日净买入康方生物82.20万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2429176635","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429176635?lang=zh_cn&edition=full","pubTime":"2024-04-24 09:31","pubTimestamp":1713922278,"startTime":"0","endTime":"0","summary":"4月23日, 南向资金增持康方生物82.20万股，连续3日增持。截止当日收盘，港股通共持有康方生物29162.77万股，占流通股33.67%。港股通增持金额前五个股分别为中国银行、腾讯控股、中国移动、农业银行、建设银行。康方生物近5个交易日下跌0.11%，港股通累计增持68.37万股；近20个交易日下跌1.37%，港股通累计增持1354.74万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404240944148b4cbc5c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404240944148b4cbc5c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429120063","title":"【港股通】康方生物(09926)：开坦尼®用于一线治疗宫颈癌的新适应症上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2429120063","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2429120063?lang=zh_cn&edition=full","pubTime":"2024-04-24 08:58","pubTimestamp":1713920326,"startTime":"0","endTime":"0","summary":"金吾财讯 | 康方生物(09926)宣布，国家药品监督管理局(“NMPA”)已于近期正式受理由公司自主研发的全球首创双特异性抗体开坦尼®(卡度尼利，PD-1/CTLA-4)联合含铂化疗联合或不联合贝伐珠单抗一线治疗持续、复发或转移性宫颈癌的新适应症上市申请(“sNDA”)。AK104–303研究是全球首个PD-1/CTLA-4双特异性抗体联合含铂化疗联合或不联合贝伐珠单抗一线治疗持续、复发或转移性宫颈癌的临床研究，是一项随机、双盲、多中心的III期临床试验，主要研究终点为无进展生存期(PFS)和总生存期(OS)。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210510/ODZjYTYwNTJhNDNjMjgyMWJhNDY2ZTQzMDQ0NzUzMTY1Mjk2OTkx.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210510/ODZjYTYwNTJhNDNjMjgyMWJhNDY2ZTQzMDQ0NzUzMTY1Mjk2OTkx.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1935641","is_publish_highlight":false,"gpt_icon":0},{"id":"2429227871","title":"康方生物(09926)：国家药监局受理开坦尼®用于一线治疗宫颈癌的新适应症上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2429227871","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429227871?lang=zh_cn&edition=full","pubTime":"2024-04-24 08:21","pubTimestamp":1713918088,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康方生物 发布公告，国家药品监督管理局已于近期正式受理由本公司自主研发的全球首创双特异性抗体开坦尼联合含铂化疗联合或不联合贝伐珠单抗一线治疗持续、复发或转移性宫颈癌的新适应症上市申请。本次sNDA意味着开坦尼将推进至宫颈癌一线治疗领域，为晚期宫颈癌全人群患者带来广泛的获益。这是开坦尼第三个适应症的上市申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1108176.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429153834","title":"港股异动 | 医药股午后拉升走强 创新药政策向好态势明显 二季度后板块有望持续转暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2429153834","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429153834?lang=zh_cn&edition=full","pubTime":"2024-04-23 13:55","pubTimestamp":1713851752,"startTime":"0","endTime":"0","summary":"消息面上，近日，北京市医保局印发《北京市支持创新医药高质量发展若干措施》。东海证券近日研报指出，今年以来包括对创新药的明确支持、集采续约条款的持续优化等，行业政策向好态势明显；二季度以后板块整体有望持续转暖向好。中长期来看，持续看好创新药、特色器械等代表新质生产力发展方向的投资机会；中短期来看，重点关注品牌中药、连锁药店、血制品等低估值、高股息，成长稳健的相关板块及个股的投资机会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107395.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429027158","title":"生物医药板块午后发力 药明合联(02268)涨8.59% 机构指行业今年依然有结构性增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2429027158","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2429027158?lang=zh_cn&edition=full","pubTime":"2024-04-23 13:53","pubTimestamp":1713851628,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物医药板块午后发力走高，药明合联 涨8.59%，荣昌生物涨6.53%，信达生物涨6.48%，康希诺生物涨6.4%，维亚生物涨5.88%，和黄医药涨5.58%，康方生物涨5.41%。华鑫证券表示，2024年1季度行业增长受到同期基数影响较为明显，如零售药店、POCT等，展望2024年全年，1季度高增长方向具有代表性，其增长趋势有望延续，医药行业依然有结构性增量。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/OTA2NWNmYzE4MTQyOTUwMjEyNTI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/OTA2NWNmYzE4MTQyOTUwMjEyNTI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1935593","is_publish_highlight":false,"gpt_icon":0},{"id":"2429179137","title":"康方生物盘中异动 股价大涨5.07%报46.601港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2429179137","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429179137?lang=zh_cn&edition=full","pubTime":"2024-04-23 13:13","pubTimestamp":1713849232,"startTime":"0","endTime":"0","summary":"2024年04月23日下午盘13时13分，康方生物股票出现波动，股价大幅上涨5.07%。截至发稿，该股报46.601港元/股，成交量182.6万股，换手率0.21%，振幅5.98%。资金方面，该股资金流入4870.99万港元，流出2291.24万港元。最近的财报数据显示，该股实现营业收入49.95亿港元，净利润22.38亿港元，每股收益2.67港元，毛利48.48亿港元，市盈率18.03倍。康方生物股票所在的生物技术行业中，整体涨幅为0.56%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042313135279228204&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042313135279228204&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428876046","title":"康方生物04月19日主力资金流出511万元 连续5日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2428876046","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428876046?lang=zh_cn&edition=full","pubTime":"2024-04-19 16:15","pubTimestamp":1713514543,"startTime":"0","endTime":"0","summary":"04月19日, 康方生物股价跌3.30%，报收43.90元，成交金额3.02亿元，换手率0.80%，振幅6.17%，量比2.15。康方生物今日主力资金净流出511万元，连续5日净流出，上一交易日主力净流出599万元，今日环比减少14.69%。该股近5个交易日下跌11.31%，主力资金累计净流出2666万元；近20日主力资金累计净流入1.39亿元，其中净流入天数为10日。该股主力净额占比0.01%，港股市场排名2445/2628。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191616018794af02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191616018794af02&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428700572","title":"康方生物盘中异动 快速下挫5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428700572","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428700572?lang=zh_cn&edition=full","pubTime":"2024-04-19 10:20","pubTimestamp":1713493213,"startTime":"0","endTime":"0","summary":"2024年04月19日早盘10时20分，康方生物股票出现波动，股价急速下跌5.07%。截至发稿，该股报43.101港元/股，成交量212.3万股，换手率0.25%，振幅5.29%。资金方面，该股资金流入2679.53万港元，流出4585.71万港元。康方生物股票所在的生物技术行业中，整体跌幅为0.76%。其相关个股中，创胜集团-B、帝王国际投资、三叶草生物-B涨幅较大，振幅较大的相关个股有三叶草生物-B、创胜集团-B、乐普生物-B，振幅分别为12.70%、12.50%、9.30%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041910201387e81fcb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041910201387e81fcb&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428574151","title":"南向资金4月18日净卖出康方生物69.10万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2428574151","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428574151?lang=zh_cn&edition=full","pubTime":"2024-04-19 09:31","pubTimestamp":1713490292,"startTime":"0","endTime":"0","summary":"4月18日，南向资金减持康方生物69.10万股连续3日减持。截止当日收盘，港股通共持有康方生物29014.66万股，占流通股33.50%。康方生物近5个交易日下跌6.87%，港股通累计减持28.74万股；近20个交易日下跌12.44%，港股通累计增持1303.46万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404190944258b384c08&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404190944258b384c08&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428395336","title":"康方生物04月17日遭主力抛售891万元 环比增加395.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428395336","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428395336?lang=zh_cn&edition=full","pubTime":"2024-04-17 16:15","pubTimestamp":1713341722,"startTime":"0","endTime":"0","summary":"04月17日, 康方生物股价跌0.53%，报收46.75元，成交金额1.36亿元，换手率0.34%，振幅4.68%，量比0.95。康方生物今日主力资金净流出891万元，连续3日净流出，上一交易日主力净流出180万元，今日环比增加395.00%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为53.85%，平均跌幅为2.44%。该股近5个交易日下跌3.49%，主力资金累计净流入663万元；近20日主力资金累计净流入1.62亿元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171615358787fb73&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171615358787fb73&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428741365","title":"港股概念追踪 |北京支持创新医药高质量发展政策出台  机构看好国产创新药产业链崛起（附概念股）","url":"https://stock-news.laohu8.com/highlight/detail?id=2428741365","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428741365?lang=zh_cn&edition=full","pubTime":"2024-04-17 14:10","pubTimestamp":1713334218,"startTime":"0","endTime":"0","summary":"北京市医疗保障局、北京市药品监督管理局等多部门发布北京市支持创新医药高质量发展若干措施。近日，北京、广州、珠海等多地政府先后发布了支持创新药高质量发展的利好政策，从多个产业链条环节发布相应支持政策，全方位促进创新药发展。康哲药业：创新药高选择性TYK2抑制剂CMS-D001及GnRH受体拮抗剂CMS-D002获药物临床试验批准通知书。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1103769.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428354299","title":"中山康方生物医药有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2428354299","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2428354299?lang=zh_cn&edition=full","pubTime":"2024-04-17 12:11","pubTimestamp":1713327094,"startTime":"0","endTime":"0","summary":"4月17日，据CDE官网消息，中山康方生物医药有限公司、康方药业有限公司联合申请药品“AK117注射液”，获得临床试验默示许可，受理号CXSL2400104。公示信息显示，药品“AK117注射液”适应症：AK129单药或联合AK117治疗PD-1/L1抑制剂治疗失败的复发或难治性经典型霍奇金淋巴瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041712113787871c15&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041712113787871c15&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426270913","title":"康方生物04月12日获主力加仓1785万元 环比增加312.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426270913","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426270913?lang=zh_cn&edition=full","pubTime":"2024-04-12 16:16","pubTimestamp":1712909767,"startTime":"0","endTime":"0","summary":"04月12日, 康方生物股价涨1.54%，报收49.50元，成交金额2.03亿元，换手率0.47%，振幅4.00%，量比1.27。康方生物今日主力资金净流入1785万元，连续3日净流入，上一交易日主力净流入433万元，今日环比增加312.24%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为53.33%，平均涨幅为2.28%。该股近5个交易日上涨9.87%，主力资金累计净流入2134万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1.95亿元，其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404121617018b15d0de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404121617018b15d0de&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426007439","title":"【券商聚焦】中信建投维持康方生物(09926)“买入”评级 指公司投入有望在多领域加速兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2426007439","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2426007439?lang=zh_cn&edition=full","pubTime":"2024-04-10 14:38","pubTimestamp":1712731089,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投发研报指，康方生物 在AACR大会发布AK104胃癌一线数据，期中分析取得阳性结果：无论 PD-L1表达，卡度尼利联合方案相比化疗显著更优。公司在肿瘤和慢病领域持续投入，有望在多领域加速兑现。考虑到公司自研新药开发的持续深入、临床开发和商业化等方面更多的重磅里程碑的落地，维持“买入”评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/ZDcxODE0MDcxNDc0MDg4MTY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZDcxODE0MDcxNDc0MDg4MTY=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1934787","is_publish_highlight":false,"gpt_icon":0},{"id":"2426413432","title":"康方生物(09926)上涨5.04%，报49.0元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426413432","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2426413432?lang=zh_cn&edition=full","pubTime":"2024-04-09 14:31","pubTimestamp":1712644312,"startTime":"0","endTime":"0","summary":"4月9日，康方生物盘中上涨5.04%，截至14:31，报49.0元/股，成交1.38亿元。康方生物科技(开曼)有限公司是一家专注于研究、开发、生产和商业化全球病人可负担的创新抗体新药的生物制药公司，拥有独特的研发创新体系、国际化标准的GMP生产体系和先进的商业化体系。截至2023年年报，康方生物营业总收入45.26亿元、净利润20.28亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/09143140162560.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2426168131","title":"康方生物盘中异动 下午盘股价大涨5.04%报49.001港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2426168131","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426168131?lang=zh_cn&edition=full","pubTime":"2024-04-09 14:31","pubTimestamp":1712644308,"startTime":"0","endTime":"0","summary":"2024年04月09日下午盘14时31分，康方生物股票出现波动，股价大幅上涨5.04%。截至发稿，该股报49.001港元/股，成交量288.296万股，换手率0.33%，振幅4.93%。资金方面，该股资金流入6869.98万港元，流出3869.54万港元。康方生物股票所在的生物技术行业中，整体涨幅为0.82%。其相关个股中，康希诺生物、君实生物、昭衍新药涨幅较大，振幅较大的相关个股有康希诺生物、宜明昂科-B、君实生物，振幅分别为19.88%、14.88%、13.51%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240409143149791f5100&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240409143149791f5100&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426872139","title":"港股异动 | 康方生物(09926)现涨超4% 卡度尼利胃癌数据亮眼 有望推动胃癌治疗格局演变","url":"https://stock-news.laohu8.com/highlight/detail?id=2426872139","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426872139?lang=zh_cn&edition=full","pubTime":"2024-04-09 14:05","pubTimestamp":1712642708,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物(09926)现涨超4%，截至发稿，涨3.97%，报48.5港元，成交额1.25亿港元。消息面上，康方生物核心产品卡度尼利联合化疗用于一线胃或胃食管结合部（G/GEJ）腺癌的III期临床研究期中分析阳性结果于2024年美国癌症协会年会（AACR）以口头报告发布，数据整体亮眼。国泰君安指出，数据显示，卡度尼利具有全人群获益优势，有望推动胃癌治疗格局演变。目前卡度尼利的一线胃癌适应症已处于NDA阶段；一线宫颈癌适应症已达到PFS终点，有望24年内达到OS终点并递交NDA。此外，公司核心产品依沃西在全球开展多项注册性临床。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1099864.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426901276","title":"康方生物4月8日获南向资金加仓98.84万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426901276","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426901276?lang=zh_cn&edition=full","pubTime":"2024-04-09 09:31","pubTimestamp":1712626293,"startTime":"0","endTime":"0","summary":"4月8日, 南向资金增持康方生物98.84万股。截止当日收盘，港股通共持有康方生物28971.65万股，占流通股33.45%。港股通增持金额前五个股分别为小米集团-W、中国移动、中国银行、腾讯控股、中国宏桥。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404090947348756ab78&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404090947348756ab78&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425936747","title":"康方生物(09926)上涨5.1%，报47.4元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2425936747","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2425936747?lang=zh_cn&edition=full","pubTime":"2024-04-08 13:53","pubTimestamp":1712555585,"startTime":"0","endTime":"0","summary":"4月8日，康方生物盘中上涨5.1%，截至13:53，报47.4元/股，成交1.39亿元。康方生物科技(开曼)有限公司是一家专注于研究、开发、生产和商业化全球病人可负担的创新抗体新药的生物制药公司，拥有独特的研发创新体系、国际化标准的GMP生产体系和先进的商业化体系。截至2023年年报，康方生物营业总收入45.26亿元、净利润20.28亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/08135340144798.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":0.0672},{"period":"1month","weight":0.0319},{"period":"3month","weight":0.1577},{"period":"6month","weight":0.1731},{"period":"1year","weight":0.1619},{"period":"ytd","weight":0.0442}],"compareEarnings":[{"period":"1week","weight":0.0548},{"period":"1month","weight":0.0401},{"period":"3month","weight":0.0835},{"period":"6month","weight":-0.0066},{"period":"1year","weight":-0.1252},{"period":"ytd","weight":0.0139}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康方生物科技（开曼）有限公司是一家主要从事生物产品研发的投资控股公司。该公司专注于满足肿瘤、免疫及其他治疗领域在全球的未决医疗需求。该公司的主要产品包括AK104、AK105、AK112及AK109。该公司于中国市场及海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.000127},{"month":2,"riseRate":0.25,"avgChangeRate":-0.01324},{"month":3,"riseRate":0.25,"avgChangeRate":-0.055315},{"month":4,"riseRate":0.75,"avgChangeRate":0.020158},{"month":5,"riseRate":0.5,"avgChangeRate":0.023949},{"month":6,"riseRate":0.75,"avgChangeRate":0.21105},{"month":7,"riseRate":0.25,"avgChangeRate":-0.068669},{"month":8,"riseRate":0.25,"avgChangeRate":-0.053599},{"month":9,"riseRate":0.5,"avgChangeRate":-0.021692},{"month":10,"riseRate":0.75,"avgChangeRate":0.139401},{"month":11,"riseRate":1,"avgChangeRate":0.091362},{"month":12,"riseRate":0.5,"avgChangeRate":0.104965}],"exchange":"SEHK","name":"康方生物","nameEN":"AKESO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康方生物,09926,康方生物股票,康方生物股票老虎,康方生物股票老虎国际,康方生物行情,康方生物股票行情,康方生物股价,康方生物股市,康方生物股票价格,康方生物股票交易,康方生物股票购买,康方生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}